AU2001236529A1 - Combination therapy for cancer - Google Patents
Combination therapy for cancerInfo
- Publication number
- AU2001236529A1 AU2001236529A1 AU2001236529A AU3652901A AU2001236529A1 AU 2001236529 A1 AU2001236529 A1 AU 2001236529A1 AU 2001236529 A AU2001236529 A AU 2001236529A AU 3652901 A AU3652901 A AU 3652901A AU 2001236529 A1 AU2001236529 A1 AU 2001236529A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- irinotecan
- combination therapy
- temozolomide
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 3
- 229960004768 irinotecan Drugs 0.000 abstract 3
- 229960004964 temozolomide Drugs 0.000 abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method for treating a human patient afflicted with cancer, is provided in which therapeutically effective amounts of temozolomide and irinotecan are administered to such a patient. Also provided is a medical kit comprising: (a) a supply of temozolomide; (b) a supply of irinotecan; and (c) printed instructions for administering temozolomide and irinotecan to a cancer patient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17854100P | 2000-01-26 | 2000-01-26 | |
US60178541 | 2000-01-26 | ||
PCT/US2001/002372 WO2001054678A2 (en) | 2000-01-26 | 2001-01-24 | Combination therapy for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001236529A1 true AU2001236529A1 (en) | 2001-08-07 |
Family
ID=22652952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001236529A Abandoned AU2001236529A1 (en) | 2000-01-26 | 2001-01-24 | Combination therapy for cancer |
Country Status (13)
Country | Link |
---|---|
US (1) | US20030229112A1 (en) |
EP (1) | EP1251850B1 (en) |
JP (1) | JP2003521497A (en) |
AT (1) | ATE330600T1 (en) |
AU (1) | AU2001236529A1 (en) |
CA (1) | CA2397523A1 (en) |
CY (1) | CY1105564T1 (en) |
DE (1) | DE60120917T2 (en) |
DK (1) | DK1251850T3 (en) |
ES (1) | ES2263591T3 (en) |
MX (1) | MXPA02007242A (en) |
PT (1) | PT1251850E (en) |
WO (1) | WO2001054678A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002328945A1 (en) * | 2001-07-23 | 2003-02-24 | Epidauros Biotechnologie Ag | Methods for improved treatment of cancer with irinotecan based on mrp1 |
WO2007000769A2 (en) | 2005-06-29 | 2007-01-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | RECOMBINANT INTERFERON α2 (IFNα2) MUTANTS |
AU2007301686B2 (en) * | 2006-09-29 | 2013-02-14 | Cipla Limited | An improved process for the preparation of temozolomide and analogs |
US20080319039A1 (en) * | 2007-06-25 | 2008-12-25 | Jacqueline Rose Bersch | Unit dosage forms of temozolomide |
AR076784A1 (en) * | 2009-05-26 | 2011-07-06 | Nerviano Medical Sciences Srl | THERAPEUTIC COMBINATION UNDERSTANDING A PLK1 INHIBITOR AND AN ANTINEOPLASTIC AGENT |
US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
CN112263579A (en) * | 2020-11-10 | 2021-01-26 | 天津键凯科技有限公司 | Anti-tumor pharmaceutical composition and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0858341B1 (en) * | 1995-08-28 | 2001-10-24 | Schering Corporation | Combination therapy for advanced cancer comprising temozolomide and cisplatin |
US6251886B1 (en) * | 1998-12-07 | 2001-06-26 | Schering Corporation | Methods of using temozolomide in the treatment of cancers |
US6346524B1 (en) * | 1999-03-30 | 2002-02-12 | Schering Corporation | Cancer treatment with temozolomide |
-
2001
- 2001-01-24 EP EP01908685A patent/EP1251850B1/en not_active Expired - Lifetime
- 2001-01-24 PT PT01908685T patent/PT1251850E/en unknown
- 2001-01-24 JP JP2001555656A patent/JP2003521497A/en not_active Withdrawn
- 2001-01-24 DK DK01908685T patent/DK1251850T3/en active
- 2001-01-24 US US09/768,445 patent/US20030229112A1/en not_active Abandoned
- 2001-01-24 AT AT01908685T patent/ATE330600T1/en not_active IP Right Cessation
- 2001-01-24 WO PCT/US2001/002372 patent/WO2001054678A2/en active IP Right Grant
- 2001-01-24 ES ES01908685T patent/ES2263591T3/en not_active Expired - Lifetime
- 2001-01-24 MX MXPA02007242A patent/MXPA02007242A/en active IP Right Grant
- 2001-01-24 CA CA002397523A patent/CA2397523A1/en not_active Abandoned
- 2001-01-24 DE DE60120917T patent/DE60120917T2/en not_active Expired - Fee Related
- 2001-01-24 AU AU2001236529A patent/AU2001236529A1/en not_active Abandoned
-
2006
- 2006-07-31 CY CY20061101074T patent/CY1105564T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CY1105564T1 (en) | 2010-07-28 |
WO2001054678A2 (en) | 2001-08-02 |
CA2397523A1 (en) | 2001-08-02 |
DK1251850T3 (en) | 2006-10-23 |
EP1251850B1 (en) | 2006-06-21 |
DE60120917D1 (en) | 2006-08-03 |
DE60120917T2 (en) | 2007-01-25 |
ES2263591T3 (en) | 2006-12-16 |
EP1251850A2 (en) | 2002-10-30 |
JP2003521497A (en) | 2003-07-15 |
MXPA02007242A (en) | 2002-12-09 |
WO2001054678A3 (en) | 2002-01-17 |
PT1251850E (en) | 2006-10-31 |
ATE330600T1 (en) | 2006-07-15 |
US20030229112A1 (en) | 2003-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105818T1 (en) | USES OF ET743 IN THE THERAPEUTIC TREATMENT OF CANCER | |
IL195723A (en) | Use of p53 inhibitors for the preparation of medicament | |
WO2004062604A3 (en) | Treatment of cancer with 2-deoxyglucose | |
ATE302003T1 (en) | PREPARATIONS CONTAINING APOMORPHINE AND SILDENAFIL AND THEIR USE FOR TREATING ERECTILE DYSFUNCTION | |
IL182352A0 (en) | The use of et-743 in the preparation of a medicament for treating cancer and medical kits containing et-743 | |
HRP20080598T3 (en) | Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer | |
IL155781A0 (en) | Effective antitumor treatments | |
WO2005094899A8 (en) | Clusterin antisense therapy for treatment of cancer | |
CY1105564T1 (en) | COMBINATION THERAPY FOR CANCER | |
NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
GB0020504D0 (en) | Therapeutic method | |
AU5574001A (en) | Method for treatment of tumors using photodynamic therapy | |
IL159770A0 (en) | Calcium salts with cytotoxic activity | |
AU6955396A (en) | Combination therapy for advanced cancer comprising temozolomide and cisplatin | |
EP1347754A4 (en) | Compositions for adhesion prevention | |
NZ538926A (en) | Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases | |
AU2450900A (en) | Therapeutic nucleoside compound | |
IL164092A0 (en) | The use of devazepide as analgesic agent | |
WO2000033823A3 (en) | Methods of using temozolomide in the treatment of cancers | |
WO2003059334A3 (en) | Gemcitabine in the treatment of smallpox | |
UA40393A (en) | METHOD OF TREATMENT OF CHRONIC OBSTRUCTIVE BRONCHITIS | |
UA28928A (en) | Method of purulent-inflammatory desease of soft tissues | |
UA30257A (en) | METHOD OF NORMALIZATION OF TISSUE EXCHANGE AND RESTORATION OF MORPHOFUNCTIONAL CONDITION OF ORGANS AND TISSUES | |
UA23985A (en) | Method for treating inflammations of internal genital organs in girls and adolescents | |
MX9603833A (en) | Improved cancer treatment with temozolomide. |